S

Shanghai MicroPort EP Medtech Co Ltd
SSE:688351

Watchlist Manager
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Watchlist
Price: 19.98 CNY 1.16% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Shanghai MicroPort EP Medtech Co Ltd?
Write Note

Shanghai MicroPort EP Medtech Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai MicroPort EP Medtech Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
Gross Profit
ÂĄ208.5m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Gross Profit
ÂĄ1.2B
CAGR 3-Years
51%
CAGR 5-Years
48%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Gross Profit
ÂĄ3.6B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
19%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Gross Profit
ÂĄ23.8B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Gross Profit
ÂĄ2.1B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Gross Profit
ÂĄ5.5B
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicroPort EP Medtech Co Ltd
Glance View

Market Cap
9.4B CNY
Industry
Health Care

Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.

Intrinsic Value
7.21 CNY
Overvaluation 64%
Intrinsic Value
Price
S

See Also

What is Shanghai MicroPort EP Medtech Co Ltd's Gross Profit?
Gross Profit
208.5m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicroPort EP Medtech Co Ltd's Gross Profit amounts to 208.5m CNY.

What is Shanghai MicroPort EP Medtech Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 3Y
27%

Over the last year, the Gross Profit growth was 16%. The average annual Gross Profit growth rates for Shanghai MicroPort EP Medtech Co Ltd have been 27% over the past three years .

Back to Top